Cisplatin resistance and pd-l1

Author: cncx

August undefined, 2024

WebApr 11, 2024 · BackgroundProgrammed cell death-ligand 1 (PD-L1) inhibitors plus chemotherapy have made substantial progress in extensive-stage small-cell lung cancer (ES-SCLC), but the survival benefit is still limited. This study aimed to evaluate the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan (IP/IC) followed … WebNov 4, 2024 · These 13 genes identify a variety of cisplatin-resistance mechanisms including increased transport and detoxification of cisplatin, and mis-regulation of the epithelial to mesenchymal transition. Conclusions We identified gene signatures in resistant TNBC subtypes indicative of mechanisms of cisplatin.

Frontiers Camrelizumab plus platinum-irinotecan followed by ...

WebApr 14, 2024 · Autophagy Influences Hypoxia, Chemoresistance, and Stem-like Phenotype in Breast Cancer It is known that cancer stem cells are a significant contributor to the development of chemoresistance in breast cancer [ 88, 89, 90, 91 ]. Autophagy enables the survival of CSCs under hypoxia in the tumor microenvironment [ 92 ]. WebNov 30, 2024 · Cisplatin may also cause upregulation of tumor cell PD-L1, which may in part explain the additive antitumor activity of cisplatin and PD-L1/PD-1 blockade. This … oracle as 別名日本語

Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance …

WebNov 23, 2024 · It was reported that the combined administration of anti-PD-L1 antibodies and DDP significantly reduced tumor growth compared with single-agent treatments and controls . These findings indicated a key role of PD-L1 in regulating DDP resistance of cancer cells. The survival and proliferation of cancer cells require the expression of cyclin … Web14 hours ago · The results indicate that in contrast to erlotinib and cisplatin, osimertinib treatment increased a subset of the HER2 and PD-L1 positive EV population. However, the average expression of the two proteins on individual EVs was found to … WebPD-L1 high expression was observed at prespecified expression levels of 5% of all cells in a section that included at least 100 evaluable tumor cells. 10 To evaluate the CD8+TIL … oracle as400

MicroRNA‐519d‐3p antagonizes osteosarcoma resistance against cisplatin ...

Cisplatin increases PD-L1 expression and optimizes immune ... - PubMed

WebSep 9, 2016 · Here we report that cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of SCLC cells under cisplatin selection. Indeed, PD1 and PD-L1 were expressed at a higher level in lung cancer cell lines, tumor tissues, and importantly, in SCLC cells resistant to cisplatin (H69R, H82R), when … WebNov 4, 2024 · Our results suggested blockage of the cell-intrinsic PD-1/PD-L1 maybe the reason why combined PD-1/PD-L1 inhibitors and cisplatin had an increased efficacy in cervical cancer cells. oracle asfu契約WebPD-L1 increases resistance to radiation or cisplatin by stabilizing NBS1, BRCA1, and other proteins that facilitate the repair of DNA damage ( 5 ). PD-L1 also diminishes IFN-β cytotoxicity by inhibiting an IFN-β–induced STAT3/caspase-7–dependent pathway ( 6 ). oracle asm amm

"WebSep 9, 2016 · Here we report that cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of SCLC cells under cisplatin … " - Cisplatin resistance and pd-l1

Cisplatin resistance and pd-l1

Investigating PD-1/PD-L1 Checkpoint Inhibition as a Treatment …

WebSep 18, 2024 · NCBI Bookshelf WebCisplatin may also cause upregulation of tumor cell PD-L1, which may in part explain the additive antitumor activity of cisplatin and PD-L1/PD-1 blockade. This information will help in interpreting results of ongoing clinical trials combining these agents, and for comparison of potential future therapeutic combinations for the treatment of head ...

Did you know?

WebMay 28, 2024 · PD-L1 is critical for tumor cell escape from immune surveillance by inhibiting T cell function via the PD-1 receptor. Accumulating evidence demonstrates that anti-PD-L1 monoclonal antibodies might potently enhance antitumor effects in various tumors, but the effect of PD-L1 on colorectal cancer stem cells (CSCs) remains unclear. WebApr 14, 2024 · Moreover, subsequent experiments revealed that HAT1 upregulates PD-L1 expression through the action of the transcription factor BRD4, which binds to the promoter of PD-L1. ... Notably, during the development of cisplatin resistance, many changes at the genetic and epigenetic levels are evident . HAT1 has been shown to contribute to …

WebGastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer 设为首页收藏本站

WebNov 15, 2024 · Abstract. Accumulating evidence indicates that a ligand of programmed cell death receptor-1 (PD-L1) participates in the progression and recurrence of multiple malignancies, including osteosarcoma. Nevertheless, the role of PD-L1 in chemoresistance development is not fully understood. WebOct 22, 2024 · Cisplatin is an alkylating agent which induces DNA damage through the formation of cisplatin-DNA adducts, leading to cell cycle arrest and apoptosis. In the management of advanced OSCC, cisplatin-based chemotherapy or chemoradiotherapy has been considered as the first-line treatment.

WebNevertheless, the role of PD-L1 in chemoresistance development is not fully understood. In the current study, we aim to clarify the interaction of miR-519d-3p and PD-L1 in the development of cisplatin resistance. Immunohistochemistry, quantitative reverse-transcription polymerase reaction, and Western blot were used to evaluate PD-L1 …

WebMar 15, 2024 · Carboplatin-based regimens — For patients who are otherwise candidates for combination chemotherapy but are unable to receive cisplatin (eg, due to renal dysfunction, neuropathy, severe hearing loss, or heart failure), we suggest the combination of gemcitabine plus carboplatin. oracle ascp tablesWebCisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells Immune tolerance is one of the leading causes of chemotherapy resistance in carcinoma cases. oracle ascp horizontal planWebApr 13, 2024 · Consequently, miR-196a released from exosomes can confer cisplatin resistance to cancer cells by novel binding targets, CDKN1B and ING5, demonstrating that miR-196a could be a potential predictor ... oracle as 別名テーブルhttp://mars.gmu.edu/handle/1920/13265?show=full oracle asm acfsWebJul 28, 2024 · PD-L1, the ligand of PD-1, expresses universally and increases in malignant cells [ 8 ]. Recent studies indicated that both PD-1 and PD-L1 contribute to cisplatin … oracle ashburnWebApr 10, 2024 · Several therapeutically relevant markers were identified in EVs collected after cisplatin treatment, including PD-L1 and other proteins regulating PD-L1 export. … oracle ascp user guideWebImmune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non–small cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic drugs may improve the efficacy of ICB in mouse tumor models and patients with cancer. portsmouth shooting 2021